OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial introductions	72
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	61
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	60
ANGPTL4: a new mode in the regulation of intravascular lipolysis	51
Alveolar macrophages: guardians of the alveolar lipid galaxy	47
Sphingomyelins and ceramides: possible biomarkers for dementia?	41
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	37
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	35
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	33
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	32
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	29
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	23
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	18
Implementation science and genetic testing for familial hypercholesterolemia	18
Oxidized LDL receptors: a recent update	17
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	17
Familial hypercholesterolemia in children and the importance of early treatment	17
Lipid metabolism during pregnancy: consequences for mother and child	17
Nonalcoholic fatty liver disease: an update	16
Genetic determinants of pancreatitis risk in hypertriglyceridemia	15
Familial hypercholesterolemia in pregnancy	15
Editorial introductions	15
A new SPRING in lipid metabolism	15
From clinical development to real-world outcomes with inclisiran	14
Nutrition and its impact on cardiovascular disease	14

The current state of apolipoprotein E in dyslipidemia	14
The need for national and international registries of patients with elevated lipoprotein(a)	13
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	13
Editorial introduction	13
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	13
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets	13
APOE and familial hypercholesterolemia	12
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	12
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	11
In the wake of the Scandinavian Simvastatin Survival Study trial	11
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	11
Editorial introductions	11
Can small dense LDL cholesterol be estimated from the lipid profile?	11
Cardiomyocytes, sphingolipids and cardio myotoxicity	11
Strategies for management of patients with elevated lipoprotein(a)	10
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	10
Newborn screening for lipid disorders	10
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	10
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	10
Pregnancy, cardiovascular health, and microchimerism	9
Clinical associations between exercise and lipoproteins	9
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	9
Altered cardiovascular risk pattern of LDL cholesterol in older adults	9
Genetic testing for familial hypercholesterolemia	9
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	8
The pathophysiology of excess plasma-free cholesterol	8
Prevention of cardiometabolic diseases through dietary modifications	8
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	8
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	7
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	7
Clonal hematopoiesis of indeterminate potential and the evolutionary lottery in chromosome 2: does that make human atherosclerosis special?	6
Lipidomics in gestational diabetes mellitus	6
Recent lipoprotein(a) trials	6
A contemporary snapshot of familial hypercholesterolemia registries	6
Assessment of cardiovascular disease risk: a 2023 update	6
Translating guidelines into practice via implementation science: an update in lipidology	6
Editorial introductions	6
Dietary fat, telomere length and cognitive function: unravelling the complex relations	6
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	6
Atherogenic low-density lipoprotein and cardiovascular risk	5
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	5
Diagnosis of remnant hyperlipidaemia	5
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	5
How should low-density lipoprotein cholesterol be calculated in 2022?	5
Predictors of cardiovascular risk in familial hypercholesterolemia	5
Understanding the ins and outs of lipoprotein (a) metabolism	5
Therapeutic application of genome editing in dyslipidemia	5
Dietary factors and brain health	5
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	5

Regulation of cardiovascular calcification by lipids and lipoproteins	5
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	4
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	4
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	4
Genetics of remnant cholesterol	4
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	4
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	4
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	4
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	4
Editorial introduction	4
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	4
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	3
Fatty acid metabolism in cancer cells – the power of plasticity	3
Polygenic contribution for familial hypercholesterolemia (FH)	3
Editorial introductions	3
Editorial introduction	3
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	3
Macrophage SR-B1 in atherosclerotic cardiovascular disease	3
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	3
Lipids and brain inflammation in APOE4-associated dementia	3
G protein-coupled receptor 146: new insights from genetics and model systems	3
Lipoprotein (a) in familial hypercholesterolaemia	3
Editorial introductions	3
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	3
Bempedoic acid: new evidence and recommendations on use	3
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	3
PCSK9-directed therapies: an update	3
Macrophage cannibalism: efferocytosis in atherosclerosis	3